Synlett 2011(10): 1399-1402  
DOI: 10.1055/s-0030-1260561
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

A Rapid and Highly Diastereoselective Synthesis of Enantiomerically Pure (4R,5R)- and (4S,5S)-Isocytoxazone

Benjamin R. Buckley*a, Philip C. Bulman Pageb, Vickie McKeea
a Department of Chemistry, Loughborough University, Ashby Road, Loughborough, Leicestershire, LE11 3TU, UK
Fax: +44(1509)223925; e-Mail: b.r.buckley@lboro.ac.uk;
b School of Chemistry, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK
Further Information

Publication History

Received 25 February 2011
Publication Date:
13 May 2011 (online)

Abstract

A three-step protocol for the highly diastereoselective (>98%) synthesis of both (4R,5R)- and (4S,5S)-isocytoxazone from d- or l-tyrosine is reported. The diastereoselection was confirmed by X-ray crystallography. This synthesis is currently the highest yielding approach towards these enantiomerically pure biologically active oxazolidinones.

    References and Notes

  • 1 Kakeya H. Morishita M. Kobinta K. Osono M. Ishizuka M. Osada H. J. Antibiot.  1998,  51:  1126 
  • 2a Carter PH. LaPorte JR. Scherle PA. Decicco CP. Bioorg. Med. Chem. Lett.  2003,  13:  1237 
  • 2b Kumar AR. Bhaskar G. Madhan A. Rao BV. Synth. Commun.  2003,  33:  2907 
  • 2c Narina SV. Kumar TS. George S. Sudalai A. Tetrahedron Lett.  2007,  48:  65 
  • 3 Hamersak Z. Sepac D. Ziher D. Šunjic V. Synthesis  2003,  375 
  • 4a Giorgio E. Viglione RG. Zanasi R. Rosini C. J. Am. Chem. Soc.  2004,  126:  12968 
  • 4b Giorgio E. Roje M. Tanaka K. Hamersak Z. Šunjic V. Nakanishi K. Rosini C. Berova N. J. Org. Chem.  2005,  70:  6557 
  • 4c Kakeya H. Morishita M. Koshino H. Morita T. Kobayashi K. Osada H. J. Org. Chem.  1999,  64:  1052 
  • 5 Rozwadowska MD. Tomczak A. Tetrahedron: Asymmetry  2009,  20:  2048 
  • 6a Page PCB. Rassias GA. Barros D. Adel A. Buckley B. Bethell D. Smith TAD. Slawin AMZ. J. Org. Chem.  2001,  66:  6926 
  • 6b Page PCB. Barros D. Buckley BR. Marples BA. Tetrahedron: Asymmetry  2005,  16:  3488 
  • 6c Page PCB. Rassias GR. Barros D. Ardakani A. Bethell D. Merifield E. Synlett  2002,  580 
  • 6d Page PCB. Buckley BR. Barros D. Blacker AJ. Heaney H. Marples BA. Tetrahedron  2006,  62:  6607 
  • 6e Page PCB. Buckley BR. Rassias GA. Blacker AJ. Eur. J. Org. Chem.  2006,  803 
  • 6f Page PCB. Buckley BR. Heaney H. Blacker AJ. Org. Lett.  2005,  7:  375 
  • 6g Page PCB. Barros D. Buckley BR. Ardakani A. Marples BA. J. Org. Chem.  2004,  69:  3595 
  • 6h Page PCB. Buckley BR. Blacker AJ. Org. Lett.  2004,  6:  1543 
  • 7 Racioppi R. Gavagnin M. Strazzullo G. Sodano G. Tetrahedron Lett.  1990,  31:  5177 
  • 8 Macdiarmid JE. Qui LD. J. Org. Chem.  1981,  46:  1451 
  • 10 Shimamoto K. Ohfune Y. Tetrahedron Lett.  1988,  29:  5177 
  • 15 Ross AJ. Lang HL. Jackson RFW. J. Org. Chem.  2010,  75:  245 
  • 16 Sheldrick GM. Acta Crystallogr., Sect. A  2008,  64:  112 
9

O -Methyl- N - tert -butoxycarbonyl-l-tyrosine Methyl Ester (10): A solution of N-tert-butoxycarbonyl-l-tyrosine (8.00 g, 28.5 mmol) in dimethylformamide (80 mL) was cooled using an ice bath, treated with freshly ground KOH (1.72 g, 31.3 mmol), and a cooled solution of iodomethane (1.95 mL, 31.3 mmol) in dimethylformamide (20 mL) was added dropwise over 5 min. The mixture was stirred at r.t. for 30 min, cooled using an ice bath, and additional KOH (1.72 g, 31.3 mmol) and a cooled solution of iodomethane (1.95 mL, 31.3 mmol) in dimethylformamide (20 mL) was added. The mixture was stirred for 3 h, poured onto ice (150 mL), and extracted with EtOAc (3 × 75 mL). The organic layers were washed with H2O (3 × 50 mL), brine (2 × 50 mL) and dried (MgSO4). The solvent was removed under reduced pressure to afford a colourless oil. Crystallization was achieved from EtOAc-light petroleum, to give 10 as colourless crystals (6.5 g, 74%); mp 52-53 ºC; [α]²0 D +58.9 (c 1.2, CHCl3), lit.¹5 [α]²² D +59.2 (c 1.8, CHCl3). IR (film): 2976, 1746, 1716, 1612, 1515, 1391, 1366, 1248, 1175, 1058, 1034 cm. ¹H NMR (250 MHz, CDCl3): δ = 1.42 (s, 9 H), 3.01-3.11 (m, 2 H), 3.71 (s, 3 H), 3.78 (s, 3 H), 4.53 (q, 1 H, J = 5.7 Hz), 5.00 (d, 1 H, J = 6.7 Hz), 6.82 (d, 2 H, J = 8.7 Hz), 7.03 (d, 2 H, J = 8.7 Hz). ¹³C NMR (100 MHz, CDCl3): δ = 28.3, 37.6, 52.7, 54.7, 55.3, 79.9, 114.1, 128.1, 130.3, 155.1, 158.8, 172.4. HRMS: m/z calcd for C16H23NO5: 309.1576; found: 309.1578.

11

Methyl (4 S ,5 R )-5-[4-Methoxyphenyl)-1,3-oxazolidin-2-one 4-Carboxylate (11): A solution of O-methyl-N-tert-butoxycarbonyl-l-tyrosine methyl ester (10; 5.00 g, 16.2 mmol) in MeCN (200 mL) was treated with a solution of K2S2O8 (8.75 g, 32.4 mmol) in H2O (210 mL) and a solution of CuSO4 (0.52 g, 3.2 mmol) in H2O (50 mL). The mixture was heated to 70 ºC for 3 h under a blanket of N2, allowed to cool, and extracted with EtOAc (3 × 150 mL). The combined organic solutions were dried (MgSO4) and concentrated under reduced pressure to give a dark yellow oil. Column chromatography, eluting with EtOAc-light petroleum (1:10-1:1), afforded a colourless solid, which was recrystallised from EtOAc-light petroleum to give 11 as a colourless crystalline solid (2.10 g, 52%); mp 94-96 ºC; [α]²0 D +83.5 (c 1.15, CHCl3). IR (film): 3316, 2956, 2362, 2337, 1762, 1613, 1515, 1382, 1250, 1224, 1026, 834, 763 cm. ¹H NMR (400 MHz, CDCl3): δ = 3.81 (s, 3 H), 3.83 (s, 3 H), 4.31 (d, 1 H, J = 5.2 Hz), 5.56 (d, 1 H, J = 5.2 Hz), 6.81 (s, 1 H), 6.93 (d, 2 H, J = 4.8 Hz), 7.33 (d, 2 H, J = 4.8 Hz), ¹³C NMR (100 MHz, CDCl3): δ = 53.5, 55.7, 61.8, 79.9, 114.7, 127.5, 130.3, 158.6, 160.6, 170.7. HRMS: m/z [M+] calcd for C12H13NO5: 251.0794; found: 251.0794.

12

Crystal data for 11: C12H13NO5, M = 251.23, monoclinic,
a = 7.0103 (8), b =5.5734 (6), c = 15.6004 (18) Å, U = 602.01 (12) ų, space group P21, Z = 2, µ = 0.109 mm, ρ calc = 1.386 Mg/cm³. 5035 data (1542 unique, R int = 0.0157) collected on an Apex II diffractometer at 150 K. Solved by direct methods¹6 and refined by full-matrix least squares on F ². R 1[I > 2σ(I)] = 0.0298 and wR 2 (all data) = 0.0745. Goodness of fit on F ² = 1.079. CCDC No. 804096.

13

(4 R ,5 R )-Isocytoxazone ( ent -3): Methyl (4S,5R)-5-[4-methoxyphenyl]-1,3-oxazolidin-2-one 4-Carboxylate (11; 2.20 g, 8.8 mmol) was dissolved in EtOH (25 mL) and the solution was cooled using an ice bath. A solution of NaBH4 (0.70 g, 19.3 mmol) in EtOH (8 mL) was added dropwise with stirring. After the addition was complete the ice bath was removed and the mixture was stirred for 45 min. The mixture was cooled to 0 ºC and concd HCl (1.5 mL) was added, followed by H2O (15 mL). The EtOH was removed under reduced pressure and the remaining aqueous solution was extracted with EtOAc (3 × 50 mL). The combined organic solutions were dried (MgSO4), and the solvents were removed to afford an off-white solid, which was recrystal-lized from EtOAc-light petroleum to give (4R,5R)-iso-cytoxazone (ent- 3) as a colourless crystalline solid (1.75 g, 90%); mp 140-142 ºC; [α]²0 D +74.8 (c 1.08, acetone), lit.³ [α]²5 D +70 (c = 0.4, MeOH). IR (nujol): 3239, 1725, 1614, 1514, 1459, 1376, 1251, 1174, 1062, 1016, 828 cm. ¹H NMR (250 MHz, acetone-d 6): δ = 3.71-3.87 (m, 3 H), 3.86 (s, 3 H), 5.35 (d, 1 H, J = 5.3 Hz), 7.01 (d, 2 H, J = 8.6 Hz), 7.41 (d, 2 H, J = 8.6 Hz). ¹³C NMR (100 MHz, CDCl3): δ = 56.0, 63.1, 64.2, 80.4, 115.4, 128.7, 133.2, 159.6, 161.3. HRMS: m/z [M+] calcd for C11H13NO4: 223.0845; found: 223.0842.

14

See the Supporting Information for the experimental data.